(Q35623265)

9 August 2017

title

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies (English)

1 reference

metastatic renal cell carcinoma

9 August 2017

1 reference

1 reference

3

1 reference

9 August 2017

V Grünwald

1

1 reference

9 August 2017

C Seidel

2

1 reference

9 August 2017

A Ganser

4

1 reference

9 August 2017

J Busch

5

1 reference

9 August 2017

S Weikert

6

1 reference

9 August 2017

language of work or name

English

0 references

publication date

27 October 2011

1 reference

British Journal of Cancer

9 August 2017

published in

1 reference

9 August 2017

volume

105

1 reference

9 August 2017

issue

11

1 reference

9 August 2017

page(s)

1635-1639

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2011.389

9 August 2017

exact match

0 references

cites work

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242587

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242587

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242587

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242587

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242587

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242587

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242587

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242587

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

27 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2011.389

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2011.389

Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCC

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3242587

7 December 2018

Identifiers

DOI

10.1038/BJC.2011.389

1 reference

9 August 2017

1 reference

9 August 2017

1 reference